Drugmakers are growing frustrated with the National Health Service after a clawback tax unexpectedly soared, with ...

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy ...

A Goodwin Procter team has advised on British pharmaceutical giant GSK’s $1.15 billion acquisition of a US biopharmaceutical ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its ...

(RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company, for up to $1.15 billion ...

LONDON - GSK plc (LSE/NYSE: LON:GSK) has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for its investigational drug GSK'227, aimed at treating adults with ...

The Brentford, England-based pharmaceutical and biotechnology firm said it will pay USD1.00 billion upfront for IDRx, a developer of precision therapeutics for the treatment of gastrointestinal ...

(Alliance News) - GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemotherapy, to include all adult patients with primary advanced or ...

London stocks were set to fall at the open on Monday following a downbeat session in Asia. The FTSE 100 was called to open ...

The acquisition of IDRx will help GSK target a ‘major gap in the current standard of care’ related to gastrointestinal cancers.

London stocks fell in early trade on Monday as bond yields rose again, but oil majors gained in tandem with oil prices.

Drugmaker GSK has agreed to pay up to 1.15 billion US dollars (£950 million) for a US-based biopharmaceutical company which is developing rare cancer therapies. GSK said the acquisition of IDRx w ...